Unveiling 7 Analyst Insights On Zimmer Biomet Holdings
Portfolio Pulse from Benzinga Insights
Zimmer Biomet Holdings (NYSE:ZBH) has received mixed analyst ratings over the last three months, with a shift towards a more neutral stance in the last 30 days. The average 12-month price target for ZBH has increased by 5.57% to $134.29. Analyst actions include rating adjustments and price target changes, reflecting dynamic market conditions and company performance. Zimmer Biomet, a leader in orthopedic reconstructive implants, has shown a revenue growth of 6.3% but lags behind industry peers. Its net margin outperforms industry averages, yet its ROE is below benchmarks.
April 03, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Zimmer Biomet Holdings has seen a mix of analyst ratings, with a recent average price target increase to $134.29. The company's financial performance shows strong net margin and revenue growth, but ROE below industry benchmarks.
The mixed analyst ratings with a recent shift towards neutrality and the increase in the average price target suggest a cautiously optimistic outlook for ZBH. The financial performance indicators such as strong net margin and revenue growth are positive, but the below-average ROE could be a concern for potential investors. The overall impact on the stock price in the short term is likely neutral, as positive financial performance may balance out the concerns over ROE and the mixed analyst ratings.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100